Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | DUSP1 | P28562 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915045 | 0.90 | KMT2A (0.55) | KMT2AMAPTRAB9ALMNAMEN1 | |
| SCHEMBL2914954 | 0.88 | ALDH1A1 (0.46) | KMT2AMAPTRAB9ALMNAHPGD | |
| SCHEMBL14096146 | 0.87 | RAB9A (0.45) | KMT2AMAPTRAB9ALMNAHPGD | |
| SCHEMBL2915042 | 0.83 | ALDH1A1 (0.49) | KMT2AMAPTRAB9ALMNAHPGD | |
| SCHEMBL2910241 | 0.80 | ALDH1A1 (0.62) | KMT2AMAPTRAB9ALMNAHPGD | |
| Hydrochloric Acid SCHEMBL2910327 | 0.79 | ALDH1A1 (0.61) | KMT2AMAPTRAB9ALMNAHPGD | |
| SCHEMBL4360387 | 0.79 | NPC1 (0.67) | KMT2AMAPTRAB9ALMNAHPGD | |
| SCHEMBL2915259 | 0.78 | KMT2A (0.55) | KMT2AMAPTRAB9ALMNAMEN1 | |
| SCHEMBL2909645 | 0.78 | KMT2A (0.53) | KMT2AMAPTRAB9ALMNAMEN1 | |
| SCHEMBL2916193 | 0.77 | ALDH1A1 (0.46) | KMT2AMAPTRAB9ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | claimed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | claimed |
| JP-2007517887-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1709047-A2 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | claimed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | claimed |
| WO-2005067900-A2 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | KMT2A 4579/4885MAPT 4038/4885RAB9A 3144/4885 |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | NAT1, PIGS, ADORA1 | KMT2A 1884/4885MAPT 4359/4885RAB9A 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.